Navigation Links
Rosetta Genomics Reports Fourth-Quarter and Full-Year 2007 Financial Results
Date:2/29/2008

adenocarcinoma is critical for therapy, but it is often difficult to differentiate these tumors. Currently, there is no objective standardized test to aid pathologists in differentiating between the many possible tumors in the lung and pleura. Based on a few microRNA biomarkers applying the Rosetta Genomics technology, this test is being developed to separate mesothelioma from adenocarcinoma tumors including lung adenocarcinoma and metastases to the lung or to the pleura. This test is expected to be filed with the New York Department of Health in H2 2008.

- Cancer of Unknown Primary (CUP) - We continued to advance assay development of microRNA-based test for cancer of unknown primary (CUP). The test is being developed to distinguish among more than 20 possible tissues of origin, and it is expected to be filed with the New York Department of Health in H2 2008.

- Additional diagnostic tests - We continued the expansion of our microRNA-based diagnostic pipeline with cancer-related indications and indications related to women's health.

- Identified microRNAs that are potential biomarkers for differential diagnosis of the following in lung cancer: primary vs. metastases, neuroendocrine tumors vs.

- non-small cell lung cancer, lung cancer vs. thymoma, and carcinoid vs. other neuroendocrine tumors.

- Identified specific microRNAs that are markers to differentiate between primary liver and brain tumors and metastases to these organs.

- Women's health: Identified specific microRNAs that may be potential markers for preeclampsia in serum. Demonstrated correlation between microRNAs in serum and physiological conditions.

Therapeutic Programs

- Liver Cancer Therapeutic - Rosetta Genomics, in collaboration with Isis Pharmaceuticals, Inc., has entered in vivo studies on antisense oligonucleotide leads designed to inhibit a microRNA that it has identified as a potential drug target.

Collaborations and Licensing


'/>"/>

SOURCE Rosetta Genomics Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Rosetta Genomics Establishes Medical Advisory Board
2. Henry Ford Hospital and Rosetta Genomics to Develop MicroRNA-based Diagnostics for Brain Cancer
3. Rosetta Genomics Announces Initiation of Expansion of US Operations to Facilitate Expected Product Launches in 2008
4. Rosetta Genomics and Columbia University Medical Center to Develop MicroRNA-based Diagnostics for Leukemia and Non Hodgkin Lymphoma
5. Rosetta Genomics Selects PCR as Platform for its microRNA-based Diagnostics to be Launched in 2008, Licensed Nanogens MGB Probe Technology
6. Rosetta Genomics Announces Initiation of In Vivo Studies Following Successful Completion of First Milestone in MicroRNA-based Therapeutic Program for Liver Cancer
7. Rosetta Genomics Will Host and Webcast its R&D Day on Friday, October 26, 2007
8. Rosetta Genomics to Host and Webcast its R&D Day on Friday, October 26, 2007
9. Rosetta Genomics to Webcast Presentation at Maxim Group Growth Conference
10. Rosetta Genomics to Present at the American Association of Cancer Research (AACR) "Molecular Diagnostics in Cancer Therapeutic Development" Conference
11. NYU Medical Center Collaborates With Rosetta Genomics to Develop a microRNA-Based Diagnostic Test for Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... on electrons, but one of the most promising technologies ... based on light (photons) instead of electrons. First, it ... of single photons and control their direction. Researchers around ... achieve this control, but now scientists at the Niels ... of photons emitted one at a time and in ...
(Date:8/29/2014)... Pittsburgh, PA (PRWEB) August 29, 2014 ... Chairman, Hub MacDonald, and colleague Koichiro Matsuda, Horiba Scientific, ... JASIS on September 5, 2014. JASIS , Asia’s ... September 3-5, 2014, in Makuhari Messe, Japan. , ... New Tools for Bioanalysis from Single Molecules to Single ...
(Date:8/29/2014)... California (PRWEB) August 29, 2014 ... of Energy's 2014 Hydrogen Production R&D Award ... -- by splitting water using sunlight. , Shared ... (NREL) and the University of Nevada, Las Vegas ... work developing models of photoelectrochemical solar-hydrogen production and ...
(Date:8/29/2014)... August 29, 2014 Intrinsic Imaging, ... certified, GAMP® 5 compliant imaging core lab, announced ... Phase II clinical trial to assess a new ... this trial, Intrinsic Imaging will provide comprehensive imaging ... protocol and charter development, site qualification, site training ...
Breaking Biology Technology:Breakthrough in light sources for new quantum technology 2Fifth Annual U.S. Symposium at JASIS Organized by Pittcon’s Program Chairman Hub MacDonald 2Livermore Team Awarded for Hydrogen Production Research 2Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma 2
... cells is limited by a lack of methods for studying ... different methods, a team of Uppsala researchers have now provided ... on several levels at the same time. Their article is ... also show that the method can be used to determine ...
... decorative, flower-like defects in the nanomaterial graphene could have ... and mechanical properties, according to researchers at the National ... In a new paper,* the team for the first ... occur naturally or be induced to occur in graphene, ...
... of the March 11 earthquake and rolling blackouts that ... award-winning undergraduate internship program NanoJapan is scrambling to run ... U.S. undergraduates travel to Japan for lab internships, NanoJapan ... send 25-30 students to Rice University laboratories for three ...
Cached Biology Technology:Combo method reveals cells' signal systems 2Defect in graphene may present bouquet of possibilities 2Reverse NanoJapan: Rice to host 25-30 Japanese students 2
(Date:8/29/2014)... Researchers at UC Davis have made some surprising ... infection. Studying simian immunodeficiency virus (SIV), the team ... Paneth cells are early responders to viral invasion ... producing a cytokine called interleukin-1 beta (IL-1β). ... IL-1β causes breakdown of the gut epithelium that ...
(Date:8/29/2014)... the University of Texas Medical Branch at Galveston has gone ... can completely protect monkeys against a lethal dose of Ebola ... when the disease is severe. , Thomas Geisbert, professor of ... discussing advances in Ebola treatment research. The filoviruses known ... deadly of pathogens, with fatality rates of up to 90 ...
(Date:8/29/2014)... available in German . ... the natural nitrogen cycle on Earth and in biological ... thought to depend on nitrite as their source of ... Daims, a microbiologist at the University of Vienna, has ... an alternative source of energy. The oxidation of hydrogen ...
Breaking Biology News(10 mins):The early cost of HIV 2Leading Ebola researcher at UTMB says there's an effective treatment for Ebola 2Hydrogen powers important nitrogen-transforming bacteria 2Hydrogen powers important nitrogen-transforming bacteria 3
... nation,s Upper Midwest have changed greatly since the time ... coming. That,s according to research done by Lisa ... of Natural Resource Ecology and Management and her team ... entire ecosystem," said Schulte, whose research has recently been ...
... be lacking for perennial wheat to be grown on any ... Dr. Charlie Rush, Texas Agricultural Experiment Station plant pathologist., ... plant breeders, Rush is finding a groundswell of interest as ... on his perennial wheat study., Rush obtained his initial ...
... may occur, in part, because of a problem in an ... key chemical messenger in the brain, scientists have found in ... that the gene is turned on at increasingly high rates ... the brain involved in higher functions like thinking and decision-making ...
Cached Biology News:Upper Midwest forests are losing diversity, complexity, ISU study finds 2A wheat for all seasons -- and reasons 2A wheat for all seasons -- and reasons 3How schizophrenia develops: Major clues discovered 2
DTT, 25g...
...
...
Antibody specific for trimethyl-Lys27 of histone H3. Mouse monoclonal. Antigen: Synthetic peptide derived from histone H3, trimethylated at lysine 27...
Biology Products: